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Abstract
Introduction: The aims of this study were to investigate whether drug sequence (docetaxel followed by
anthracyclines or the drugs in reverse order) affects changes in the maximal standard uptake volume (SUVmax)o n
[
18F]flourodeoxyglucose positron emission tomography (FDG-PET) during neoadjuvant chemotherapy in women
with locally advanced breast cancer.
Methods: Women were randomly assigned to receive either drug sequence, and FDG-PET scans were taken at
baseline, after four cycles and after eight cycles of chemotherapy. Tumour response to chemotherapy was
evaluated based on histology from a surgical specimen collected upon completion of chemotherapy.
Results: Sixty women were enrolled into the study. Thirty-one received docetaxel followed by anthracyclines (Arm
A) and 29 received drugs in the reverse order (Arm B). Most women (83%) had ductal carcinoma and 10 women
(17%) had lobular or lobular/ductal carcinoma. All but one tumour were downstaged during therapy. Overall, there
was no significant difference in response between the two drug regimens. However, women in Arm B who
achieved complete pathological response had mean FDG-PET SUVmax reduction of 87.7% after four cycles, in
contrast to those who had no or minor pathological response. These women recorded mean SUVmax reductions of
only 27% (P < 0.01). Women in Arm A showed no significant difference in SUVmax response according to
pathological response. Sensitivity, specificity, accuracy and positive and negative predictive values were highest in
women in Arm B.
Conclusions: Our results show that SUVmax uptake by breast tumours during chemotherapy can be dependent on
the drugs used. Care must be taken when interpreting FDG-PET in settings where patients receive varied drug
protocols.
Introduction
Positron emission tomography (PET) imaging is increas-
ingly incorporated into the routine management of can-
cer therapy. The predominant tracer in use is [
18F]
flourodeoxyglucose (FDG), based on the well-known
increased glucose requirement of cancer cells [1]. FDG-
PET over the past few years has demonstrated promise
in the assessment of breast cancer response during
chemotherapy, thus facilitating clinical decisions regard-
ing patient management and providing valuable
information about ways to tailor therapy to individual
patient requirement [2-6].
It has been established for over a decade now that
patients who achieve a complete pathological response
(cPR) in the primary breast tumour and the axillary
lymph nodes have improved rates of disease-free survi-
val [7-10]. Only 20 to 30% of patients, however, respond
to treatment with cPR [11]. The majority of patients
achieve a partial pathological response (pPR) to che-
motherapy, and these patients are at higher risk of locor-
egional recurrence than those patients with a cPR [8]. It
is therefore imperative to assess tumour response to
treatment as early as possible in order to identify those
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therapy regimen, to direct appropriate treatment and to
spare patients unnecessary chemotherapy. Conventional
imaging, such as mammography and ultrasound, provide
only information on anatomical changes in tumour mor-
phology and size. Any residual masses present after com-
pletion of chemotherapy may be composed of viable
tumour cells and/or fibrotic tissue, but conventional ima-
ging modalities are largely unable to differentiate
between the different cell types. Histopathology is still
required in order to accurately characterise the remain-
ing masses.
Since tumours undergo changes in metabolism before
apparent changes in size, it is important to evaluate
functional changes as early as possible during treatment.
Several previous studies have shown that high baseline
uptake of FDG by the tumour is associated with poorer
survival compared with tumours with lower uptake
[12-14]. It has also been demonstrated that a significant
reduction in glucose uptake on FDG-PET during or
after chemotherapy can predict cPR [4,5,15,16]. The
information obtained from FDG-PET studies to date
further suggests that changes in glucose uptake by the
tumour are independent of other, traditional, predictive
breast cancer markers [17]. The impetus now is to iden-
tify chemosensitive tumours as early as possible during
treatment. One study has recently demonstrated that a
reduction in glucose uptake after just one cycle of
neoadjuvant chemotherapy is predictive of cPR [4].
Many of the reported studies, however, investigated
small samples of patients undergoing various different
chemotherapeutic regimens. We still know little about
the functional changes of tumours in response to speci-
fic drug regimens. Hence, we designed the present pro-
spective study to analyse serial changes in tumours of
women with locally advanced breast cancer undergoing
neoadjuvant chemotherapy with docetaxel followed by
anthracycline-based chemotherapy (FEC100), or of
women undergoing FEC100 treatment followed by doce-
taxel using FDG-PET, mammography, ultrasound and
clinical assessment - and to compare these changes with
histological changes in sequential biopsies.
Materials and methods
Patient selection
Women presenting consecutively with locally advanced
breast cancer TMN stage T2 to T4, N0 to N3, M0
between June 2004 and June 2008 were invited to parti-
cipate in the study. The diagnosis was confirmed by
core needle biopsy and histopathology in all patients
prior to enrolment into the study.
The inclusion criteria were: histologically or cytolo-
gically proven invasive adenocarcinoma, age ≥ 18,
Karnofsky performance status index ≥ 80%, and
adequate haematology parameters, renal and hepatic
function.
Patients with prior history of breast cancer or other
neoplasms, with other serious medical conditions - such
as congestive heart failure, significant neurological or
psychiatric disorders, active uncontrolled infection,
active ulcers, unstable diabetes mellitus - undergoing
concurrent treatment with other experimental drugs or
hormonal agents, or who were pregnant were excluded
from the study.
The study was approved by the human research ethics
committee at our institution and all women gave writ-
ten, informed consent.
Study design
The women were randomised using a computer-gener-
ated random number allocation to receive either four
cycles of docetaxel (100 mg/m
2), followed by four cycles
of combined fluorouracil (500 mg/m
2), epirubicin
( 1 00m g / m
2) and cyclophosphamide (500 mg/m
2)
(FEC100) (Arm 1), or the reverse order of drugs
(FEC100 followed by docetaxel) (Arm 2).
At baseline, prior to commencement of chemotherapy,
all women underwent a clinical examination followed by
mammography, ultrasound and FDG-PET. All examina-
tions and imaging were carried out within 4 weeks of
commencement of treatment. Imaging (all three modal-
ities) was repeated after the initial four cycles of either
docetaxel or FEC100 and again upon completion of the
chemotherapy. All imaging was carried out at the same
clinic using the same equipment. The pathological
tumour response (gold standard) was assessed after sur-
gical resection upon completion of the treatment.
Drug regimen
All patients received either docetaxel followed by
FEC100 or the same drugs in reverse order prior to sur-
gical resection. Each drug was delivered every 21 days
for four cycles. Each subject received a total of eight
cycles of chemotherapy over 24 weeks. Supportive care
included antiemetics and granulocyte-stimulating factor
as per American Society of Clinical Oncology guidelines.
Clinical assessment
Tumours were measured with callipers, with the two
largest diameters of the tumour recorded and multi-
plied. Tumour sizes at the second and third examina-
tions were compared with baseline measurements and
classified into either complete clinical response (full
resolution of the palpable mass), partial resolution
of the mass (> 50%) or minimal resolution or clinical
progression of the mass.
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Bidimensional tumour measurements were taken in two
planes. When two or more tumours were present, the
largest tumour was used to calculate the tumour size
and response to treatment. The area of the tumour was
calculated in each of the two projections (using the for-
mula for an area of an ellipse) and the two values were
added together. Changes in tumour size were recorded
as the percentage change from baseline of the combined
area measurement.
Ultrasound measurements
Both breasts and axillas were scanned at each time point
at the same site using a Phillips ATL HDI 5000 with a
12.5 MHz linear transducer. Tumours were visualised in
the transverse and sagittal planes. The tumour volumes
were calculated at each time point using three measure-
ments for an ellipsoid volume [18]:
volume length width thickness =× × ×  /6 (1)
When more than one tumour was present, the largest
tumour was used and compared in subsequent
examinations.
FDG-PET protocol and imaging
PET scans were performed using a dual-modality Sie-
mens Biograph 2 PET/CT scanner (PET, Siemns Medical
Imaging, Knoxville, Tenessee, USA; CT, Siemens Medical
Imaging, Forchheim, Bavaria, Germany), which consists
of a two-row spiral CT and full-ring bismuth-germanate
PET. Patients were advised to fast for at least 6 hours
prior to the scan. Blood glucose concentrations were
measured before the tracer (FDG) was injected. If the
blood glucose level was < 12 mmol/l, the patient was
given diluted contrast material orally and injected with
between 8 and 10 mCi FDG via an intravenous cannula.
The patient was then rested for 60 minutes prior to ima-
ging as per our routine protocol. Variations in waiting
time due to technical or workflow factors were restricted
to between 45 and 75 minutes (60 ± 15 minutes).
Imaging was performed from the base of skull to just
inferior of the ischial tuberosities. Images were acquired
in three-dimensional mode and were reconstructed with
an iterative technique using an ordered subset expecta-
tion-maximisation algorithm incorporating CT-based
attenuation correction. The following formula was used
for the acquisition of the standardised uptake volume
(SUV) in our study:
I scale I dose weight suv Act Tstart =× × (/ ( / ,) ) 1 000 (2)
where Isuv is the image pixel value (SUV units), IAct is
the image pixel value (Bq/cm
3) corrected for the start
acquisition start time, doseTstart is the injected dose cor-
rected for the acquisition time, weight is the patient
weight (kg), and scale is the multiplier applied to SUV
values.
The patient volume of distribution is approximated by
the water equivalent to the patient weight. SUV values
typically range from 0 to 10 after applying a scaling fac-
tor suitable for the Syngo™ software system (Siemens
Medical Imaging, Forchheim, Bavaria, Germany).
All cases were reviewed by a team of five radiologists
with extensive experience in nuclear medicine, as well
as a nuclear medicine physician using a Siemen’se S o f t
workstation to review the PET, CT and fused images.
All five radiologists and the nuclear medicine physician
formed a consensus agreement prior to the study to
standardise measurements of SUV uptake. Regions of
interest were drawn using a three-dimensional contour
encompassing axial, sagittal and coronal planes traced
by the eSoft software after selecting the area of increas-
ing FDG uptake in the primary breast tumour and
involved axillary nodes. The maximum standardised
uptake value (SUVmax) within this region of interest was
calculated, and standardised according to body weight,
dose of administered FDG and time to imaging. Partial
volume correction or correction for blood sugar level
was not performed. If more than one FDG avid breast
lesion was identified, the lesion with the highest SUVmax
was chosen as the target lesion for serial comparison.
This same procedure was performed for any axillary
nodal involvement.
The metabolic response of the tumour to chemother-
apy was analysed using the SUVmax values obtained on
FDG-PET during and after treatment according to the
following formula:
Δ= × − SUV SUV baseline SUV post-treatment SUV ba (%) ( ) / max max max 100 s seline (3)
All PET readers were blinded to the clinical informa-
tion, as well as the mammography and ultrasound
reports of all patients. The only information provided to
the readers was the reports of previous FDG-PET ima-
ging, which were required for the mid-treatment and
post-treatment reports.
Pathologic evaluation
Biopsy samples collected at baseline and after four
cycles of chemotherapy were analysed by the consultant
anatomical pathologist at our institution according to
standard protocols. Tumour samples were fixed in 10%
formaldehyde and were embedded in paraffin. Sections
w e r ec u ta t5μm thickness and stained with H & E.
The tumour type, grade and extent were reported, as
well as the oestrogen receptor, progesterone receptor
and HER2 status.
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cimen was used for the definitive outcome measure.
Patients were classified into three groups according to
their pathological response. Group 1 consisted of
patients who were clear of tumour in surgical speci-
mens, including nodes (cPR); Group 2 consisted of
patients with either a small residual tumour mass
(≥ 80% reduction) or clear nodes (pPR); and Group 3
included patients that could not be classified into
Groups 1 or 2. All pathological assessments were carried
out blinded to the clinical and imaging findings.
Statistical analysis
Comparison of demographic and tumour characteristics
between the two groups of patients were carried out
using the Mann-Whitney U test. Comparison of the
SUVmax tumour uptake of each group between baseline
and at the midpoint or after treatment was made using
the Kruskal-Wallis test. Differences in sample sizes
between two groups were analysed using chi-square
tests or Fisher’s exact tests. Comparison of SUVmax
uptake values at each time point between the two
groups of patients was made using the Mann-Whitney
U test. Cutoff values ≥ 75% reduction in SUVmax from
baseline were used to assess sensitivity, specificity, posi-
tive predictive value, negative predictive value and accu-
racy in both treatment arms. This cutoff value was
chosen to fit with the published literature and to over-
ride any minor changes in SUV measurements due to
variation in technical factors. Significance was afforded
when P < 0.05. All statistical analyses were carried out
using SPSS, version 16 (SPSS Inc., Chicago, IL, USA).
Results
Sixty-eight patients were recruited into the study. Of
these patients, one withdrew from the study and seven
had not completed treatment and evaluation at the time
of analysis. These patients were not included in the final
analysis. The final number of participants therefore
included 31 patients who were randomised to receive
docetaxel followed by FEC100 and 29 patients who
received the same drugs in reverse order.
Tables 1 and 2 demonstrate the demographic charac-
teristics of patients and tumour characteristics according
to drug regimen used. There was no significant differ-
ence in any of the patient or tumour parameters studied
between the two groups of patients. The majority of
patients (50/60, 83%) presented with ductal carcinoma.
Seven patients (11.6%) had lobular carcinoma and three
patients (5%) had mixed ductal/lobular carcinoma. Most
patients (33/60, 55%) had high-grade tumours. Thirty-
seven out of 60 patients (61.6%) were oestrogen recep-
tor-positive. Although more of these patients were ran-
domised to receive docetaxel initially rather than
FEC100 (71% compared with 52%, respectively), the dif-
ference in proportion was not significant. Similarly, the
proportions of women who were progesterone receptor-
positive and HER2-positive were not significantly differ-
ent between the two groups. The proportion of women
who underwent mastectomy or a wide local excision
upon completion of chemotherapy was not statistically
different between the two groups. The median (ranges)
resting time prior to PET imaging was 60 minutes (45
to 75 minutes).
Tumour size on mammography and ultrasound and
the SUV uptake on FDG-PET were not significantly dif-
ferent between the two groups of patients at baseline
(Table 2). The median (range) SUVmax uptake for all
women was 6.5 (1.58 to 26.6). Higher baseline SUVmax
uptake was associated with higher rates of final patholo-
gical response, although statistical significance was not
reached (Figure 1).
The numbers of tumours that were classified as cPR,
as pPR and as pathological r e s p o n s en o ti n c l u d e di n
cPR or pPR are presented in Table 3. All but one
Table 1 Demographic and tumour characteristics of
women undergoing neoadjuvant chemotherapy
according to drug regimen
Characteristic TAX ! FEC FEC ! TAX P value
a
Age 52 (37-70) 48 (30-66) 0.04
b
Pathology type
Ductal 25/31 (80.6) 25/29 (86.2) 1.00
Ductal/lobular 2/31 (6.5) 1/29 (3.4) n/a
Lobular 4/31 (13.4) 3/29 (10.3) n/a
Pathology grade
Low 4/31 (12.9) 2/29 (6.9) 0.41
Medium 11/31 (35.5) 10/29 (34.5) 0.82
High 16/31 (51.6) 17/29 (58.6) 0.86
Oestrogen receptor status
Negative 10/31 (32.2) 13/29 (44.8) 0.29
Positive 21/31 (67.7) 16/29 (55.2) 0.25
Progesterone receptor status
Negative 16/31 (51.6) 18/29 (62.1) 0.60
Positive 15/31 (48.4) 11/29 (37.9) 0.33
HER2 status
c
Negative 17/29 (58.6) 16/29 (55.2) 1.00
Positive 12/29 (41.4) 13/29 (44.8) 1.00
Surgical procedure
d
Mastectomy 16/30 (53.3) 17/29 (58.6) 0.86
Wide local excision 13/30 (43.3) 12/29 (41.3) 0.84
Partial mastectomy 1/30 (3.3) 0/29 (0.0) n/a
Demographic and tumour characteristics of women undergoing neoadjuvant
chemotherapy for locally advanced breast cancer according to drug regimen
(n = 34/group). TAX, docetaxel (Taxotere®); FEC, combined flourouracil-
epirubicin-cyclophosphamide anthracycline-based chemotherapy; n/a, not
available. Data presented as median (range) or n/N (%).
aChi-square test.
bMann-Whitney U test.
cNot available for two patients in Arm 1 (TAX ® FEC).
dOne woman in Arm 1 declined surgery.
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therapy. Overall, 23% of tumours (14/60) were classified
as having undergone a complete pathological response.
Thirty per cent of tumours (18/60) underwent a partial
response, and the other tumours (28/60 (47%) recorded
only minor or no changes during chemotherapy. There
was no significant difference in tumour response
between the two drug regimens (P > 0.05).
Table 4 demonstrates the reduction in tumour
volumes after four and eight cycles of chemotherapy as
observed on mammography, ultrasound and FDG-PET
according to the drug given. There was no statistically
significant difference between the two groups of patients
when comparing tumour volume reduction or SUVmax
uptake on either imaging modality. The only significant
difference observed was associated with SUVmax uptake
after four cycles of chemotherapy with anthracyclines.
In this group of women, minor or no final pathological
response was associated with minimal reduction of
SUVmax uptake compared with women receiving doce-
taxel (P = 0.01). These outcomes are also highlighted in
Figure 2. Women receiving FEC100 first who achieved a
cPR had a median reduction of SUVmax of 87.7% from
baseline (Figure 2a). In contrast, those on the same drug
whose tumour recorded no or only minor pathological
response had a median reduction of only 27% (Figure
2 b ) .T h e s ed a t aa r es i g n i f i c a n t l yd i f f e r e n tf r o mt h o s eb y
women who received docetaxel initially (P = 0.01). This
group had no significant difference in the median
SUVmax reduction according to pathological response.
The percentage reduction in SUVmax uptake after all
eight cycles is shown in Figure 3. There were no signifi-
cant differences between the two drug sequences in
terms of pathological response (P > 0.05).
The sensitivity, specificity, positive predictive value,
negative predictive value and accuracy rates for both
treatment arms are presented in Table 5. Highest sensi-
tivity (0.87) was obtained for SUVmax reduction after
chemotherapy with FEC100 (Arm B). In contrast, sensi-
tivity was 0.83 for women in Arm A. Specificity and
overall accuracy was best among women who received
Arm B (0.76 and 0.79, respectively). Similarly, both posi-
tive and negative predictive values scored highest in this
group of women (0.58 and 0.94, respectively).
The proportion of women who achieved SUVmax
reduction ≥ 75% after four cycles of chemotherapy in
either treatment arm was also compared according to
nodal status at surgery (Table 6). There was no differ-
ence between the proportion of women with ≥ 75%
reduction of SUVmax in either Arm A or Arm B (P =
0.63). Overall, women with ≥ 75% reduction of SUVmax
Table 2 Breast tumour characteristics on mammography, ultrasound and PET at baseline according to drug regimen
TAX ! FEC FEC ! TAX P value
a
Total number 31 29
Ultrasound (volume)
b 10,669 (702 to 169,221) 11,344 (919 to 121,428) 0.49
Mammography (volume)
c 1,685 (0 to 7,487) 1,739 (0 to 5,749) 0.95
PET (SUVmax) 6.76 (1.58 to 24.8) 6.26 (2.3 to 26.6) 0.98
Data presented as median (range). TAX, docetaxel (Taxotere®); FEC, combined flourouracil-epirubicin-cyclophosphamide anthracycline-based chemotherapy; PET,
positron emission tomography; SUVmax, maximal standard uptake volume.
aMann-Whitney U test.
bVolume based on calculation of elliptical tumour shape.
cVolume based on the sum of areas in the craniocaudal and mediolateral oblique appearance.
Figure 1 Standard uptake values prior to neoadjuvant
chemotherapy according to pathological response upon
completion of chemotherapy. The raw standardised uptake
volume (SUV) values are based on those provided by the baseline
[
18F]flourodeoxyglucose-positron emission tomography scan. Data
depict the median, interquartile ranges and total ranges
(N/complete = 14, N/partial = 18, N/minor = 28).
Table 3 Number of tumours classified as complete,
partial or minor pathological response according to drug
regimen
Response TAX ! FEC FEC ! TAX Total (all women)
cPR 6/31 (19) 8/29 (28) 14/60 (23)
pPR 9/31 (29) 9/29 (31) 18/60 (30)
mPR 16/31 (52) 12/29 (41) 28/60 (47)
Number of tumours classified as a complete pathological response (cPR),
partial pathological response (pPR) or minor pathological response (mPR) after
completion of neoadjuvant chemotherapy according to drug regimen. Data
presented as n/N (%). TAX, docetaxel (Taxotere®); FEC, combined flourouracil-
epirubicin-cyclophosphamide anthracycline-based chemotherapy.
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at surgery (P = 0.13). There was no statistical difference
between the proportion of women with negative nodes
w h ow e r ei ne i t h e rA r mAo rA r mB( P =0 . 9 ) .A m o n g
those with positive nodes, however, the majority were
women who had received docetaxel rather than FEC100
initially (90% versus 10%, respectively; P = 0.001).
The histological cancer category (ductal, n =5 0v s .
lobular or lobular/ductal, n = 10) did not influence the
baseline SUVmax uptake (P = 0.48) or that recorded at
the halfway point or at the end of treatment (P =0 . 9 6
and P = 0.51, respectively; Table 7). Of the 10 women
with lobular or lobular/ductal cancer, seven (70%) had
residual nodal disease upon completion. This observa-
tion compares with 26/50 (52%) of women with ductal
cancer (P = 0.4).
Discussion
Women who present with locally advanced breast can-
cer are today routinely managed using neoadjuvant
chemotherapy, with the aim of downstaging the primary
tumour before surgery. The most commonly used che-
motherapeutic drug in this setting is docetaxel. Sequen-
tial anthracycline-based chemotherapeutic drugs are
increasingly used but little information is so far available
on the sensitivity of the tumours to these drug regimens
during treatment. The standard sequence of drugs for
adjuvant therapy has to date involved anthracyclines fol-
lowed by taxanes, but phase II trials have recently sug-
gested that the reverse sequence may improve efficacy
and lower toxicity [19]. In our neoadjuvant setting,
there was no significant difference in the efficacy
between the two drug regimens. In fact, slightly more
women reported a complete pathological response when
treated first with FEC100 compared with docetaxel (27%
versus 19%, P = 0.46).
As expected, mammographic and ultrasound measure-
ments of the breast tumours did not prove useful pre-
dictors of tumour response. These traditional imaging
modalities utilise tumour size as a measure of tumour
cell kill. Such criteria have been used for over 50 years
but their clinical usefulness remains limited. Functional
imaging has more recently moved to the forefront of
these investigations. PET with or without co-registration
of CT using the radiolabelled glucose analogue FDG
shows promise for diagnosis, for staging and as a predic-
tive marker of tumour response for a range of tumours,
because changes in glucose metabolism occur prior to
any significant changes in tumour size [20].
Results in breast cancer patients to date have shown
that SUV on FDG-PET after only one or two cycles of
chemotherapy can be used to measure early response,
with recorded sensitivities of between 61 and 100% and
specificities of between 75 and 100% [15,21-24]. Analysis
of these outcomes is difficult, however, since the disease
stage, the definition of response, the drugs and sequence
of drugs used, the calculation of FDG uptake and the
cutoff points used to evaluate sensitivities and specifici-
ties varied among the patient cohorts. Further, most of
these studies evaluated small populations (< 25 partici-
pants) - with the exception of the study by Rousseau
and colleagues that evaluated 64 patients with stage II
and III breast cancer [22], and the study by Smith
and colleagues who investigated 31 women with large
(> 3 cm) breast tumours [25].
One aspect of these studies that has not received a lot
of attention is the SUV uptake in response to the drug
regimen used. We hypothesised that the drug regimen
Table 4 Reduction in tumour volumes after four and eight cycles of chemotherapy according to drug regimen
TAX ! FEC FEC ! TAX P value
a
Total number 31 29
SUVmax reduction after four cycles
Ultrasound 80.6 (-271 to 100) 76.0 (-195 to 100) 0.89
Mammography 54.4 (-100 to 100) 50.7 (-337 to 100) 0.36
PET 75.0 (-11 to 100) 62.7 (-29 to 100) 0.16
According to final pathological response
Complete response 77.3 (-12 to 100) 82.8 (22 to 100) 0.81
Partial response 81.8 (6 to 100) 73.9 (-28 to 100) 0.79
Minor/no response 67.0 (33 to 100) 27.0 (-25 to 68) 0.01
SUVmax reduction after eight cycles
Ultrasound 91.9 (-5.6 to 100) 92.5 (-155 to 100) 0.95
Mammography 77.3 (-119 to 100) 77.5 (-84 to 100) 0.74
PET 84.1 (8.2 to 100) 91.1 (-4.8 to 100) 0.36
Percentage reduction in tumour volumes on mammography and ultrasound, and maximal standard uptake volumes (SUVmax)o n[
18F]flourodeoxyglucose positron
emission tomography (PET) after four and eight cycles of chemotherapy according to drug regimen. Data presented as median (range). TAX, docetaxel
(Taxotere®); FEC, combined flourouracil-epirubicin-cyclophosphamide anthracycline-based chemotherapy.
aMann-Whitney U test.
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on serial PET scans because different drugs target differ-
ent biological actions in the cancer cells. Most studies to
date have all evaluated FDG-PET in cohorts of women
who received various drugs with a range of dosage and
sequences. It is thus difficult to assess the true useful-
n e s so fP E Ta sap r e d i c t o ro ft u m o u rr e s p o n s et o
treatment. In general, however, the literature has
demonstrated that tumours with high levels of FDG
uptake at baseline are more likely to achieve a complete
pathological response [14,22,24,25]. These findings were
confirmed in our study.
Women in our cohort who recorded SUVmax reduc-
tions > 75% after four cycles of chemotherapy were
m o r el i k e l yt oa c h i e v eac P Ro ft h et u m o u r .F u r t h e r ,
tumours with SUVmax reductions < 30% after four cycles
of FEC100 were more likely to remain insensitive to the
treatment regardless of the subsequent use of docetaxel.
Sensitivity, specificity, positive and negative predictive
values, as well as overall accuracy were highest (when
the 75% cutoff value was used) among women receiving
FEC100 initially. Berriolo-Riedinger and colleagues
achieved sensitivities and specificities of 0.91 and 0.86,
Figure 2 Reduction in maximal standardised uptake volume
after four cycles of neoadjuvant chemotherapy. Percentage
reduction in maximal standardised uptake volume (SUVmax) after
four cycles of neoadjuvant chemotherapy according to pathological
response obtained upon completion of chemotherapy. (a)
Reductions in SUVmax after four cycles of docetaxel (Taxotere®)
(TAX). (b) Reductions in SUVmax after four cycles of anthracycline-
based fluorouracil, epirubicin and cyclophosphamide (FEC). Data
depict the median, interquartile ranges and total ranges. (a) N/
complete = 6, N/partial = 9, N/minor = 16. (b) N/complete = 8, N/
partial = 9, N/minor = 12.
Figure 3 Reduction in maximal standardised uptake volume
after eight cycles of neoadjuvant chemotherapy. Percentage
reduction in maximal standardised uptake volume (SUVmax) from
baseline after eight cycles of neoadjuvant chemotherapy according
to pathological response obtained upon completion of
chemotherapy. (a) Reductions in SUVmax after four cycles with
docetaxel (Taxotere®) (TAX) followed by four cycles with
anthracycline-based fluorouracil, epirubicin and cyclophosphamide
(FEC). (b) Reductions in SUVmax after four cycles with FEC followed
by four cycles with TAX. Data depict the median, interquartile
ranges and total ranges. (a) N/complete = 6, N/partial = 9, N/minor
= 16. (b) N N/complete = 7, N/partial = 9, N/minor = 12).
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however, women received four different treatment
protocols.
Sensitivity of 0.77 and specificity of 0.80 were achieved
in a study of 50 women with very large breast tumours
(mean size 4.3 cm) who had FDG-PET before and after
two cycles of chemotherapy with epirubicin and cyclo-
phosphamide and, if axillary nodes were positive, addi-
tional taxanes [24]. Rousseau and colleagues achieved
sensitivities and specificities of 0.61 and 0.96, respec-
tively, in their cohort of women using the 60% cutoff
value after two cycles [22]. Our comparative values
(when calculating a 60% cutoff value) after four cycles
are 0.87 and 0.56 in women receiving FEC100 and are
0.83 and 0.32 in women receiving docetaxel. These
values are similar to those recently reported by Jung and
colleagues [26]. In their study, 66 women were divided
into two groups, with 31 women receiving docetaxel
plus capecitabine and the other 31 women receiving
doxorubicin plus cyclophosphamide. FDG-PET was car-
ried out before and after four cycles of chemotherapy.
The authors used an 84.8% cutoff value to achieve sensi-
tivity and specificity values of 70% and 69.6%, respec-
tively [26]. The patients were not analysed according to
drugs used, but were evaluated as a whole group.
In an earlier study, patients receiving cyclophospha-
mide, doxorubicin, vincristine and prednisolone with or
without docetaxel were scanned using FGD-PET after
one cycle and four cycles of treatment [25]. There was
no difference in the SUVmax reduction between the two
treatment regimens used at either time point. Using a
20% reduction in SUV as the cutoff value, this study
recorded sensitivity and specificity values of 0.90 and
0.74, respectively [25]. The patients included in that
study had locally advanced cancer > 3 cm, which may
have contributed to the relatively high sensitivity
achieved. In our study, patients were included if their
cancer was > 2 cm in size. Our less restrictive inclusion
criteria may hence have resulted in the lower sensitivity
and specificity values since the sensitivity of FDG-PET
is known to be lower when the tumours are smaller
[17].
It is interesting to compare the different drug-induced
tumour responses observed on PET. The overall reduc-
tion in tumour volume was similar in all imaging mod-
alities investigated regardless of the drugs used
(Table 3). The bulk of tumour reduction occurred dur-
ing the first four cycles. Women who received FEC100
and who had a median SUVmax reduction of only 27%
or less, however, were significantly more likely to have
treatment-resistant tumours (P = 0.01). In contrast,
tumours of women who had received docetaxel could
not be easily stratified. Our results further show that
women who reported reductions of SUVmax uptake ≥
75% halfway through treatment were significantly more
likely to have positive nodes upon completion of che-
motherapy if they had received docetaxel initially (90%
vs. 10%) (Table 5). This association has not previously
been reported. Since nodal status is an important prog-
nostic indicator of overall survival and recurrence,
further investigations in larger cohorts of women with
adequate follow up of at least 5 years are required.
Our results demonstrate that the usefulness of PET in
predicting tumour response can be influenced by the
type of drugs used. This is an important consideration
in the evaluation of PET during chemotherapy. All
Table 5 Sensitivities, specificities, positive and negative
predictive values and accuracy rates after four cycles of
chemotherapy
All women TAX ! FEC FEC ! TAX
Total number 60 31 29
Sensitivity 0.78 0.66 0.87
Specificity 0.60 0.48 0.76
Positive predictive value 0.37 0.23 0.58
Negative predictive value 0.90 0.85 0.94
Accuracy 0.65 0.51 0.79
Sensitivities, specificities, positive and negative predictive values and accuracy
rates for [
18F]flourodeoxyglucose positron emission tomography based on a
75% reduction of maximal standard uptake volume after four cycles of
chemotherapy. TAX, docetaxel (Taxotere®); FEC, combined flourouracil-
epirubicin-cyclophosphamide anthracycline-based chemotherapy.
Table 6 Response of women to neoadjuvant
chemotherapy according to final nodal status
All women TAX!FEC FEC!TAX P value
a
≥ 75% reduction
in SUVmax
28/57 (49.1) 17/28 (60.7) 11/28 (39.3) 0.63
Node-negative 18/28 (64.2) 8/18 (44.4) 10/18 (55.5) 0.9
Node-positive 10/28 (35.7) 9/10 (90.0) 1/10 (10.0) 0.001
Response of women to neoadjuvant chemotherapy according to final nodal
status (positive or negative nodes at surgery). Women were stratified
according to drug sequence and > 75% reduction in maximal standard
uptake volume (SUVmax)o f[
18F]flourodeoxyglucose after four cycles. Data
presented as n/N (%) (total number = 57). TAX, docetaxel (Taxotere®); FEC,
combined flourouracil-epirubicin-cyclophosphamide anthracycline-based
chemotherapy.
aChi-square test (comparison of the two treatment arms).
Table 7 PET SUVmax at baseline and after four cycles of
chemotherapy according to histological cancer category
SUVmax Ductal
(n = 50)
Lobular/
lobular-ductal
(n = 10)
P value
a
Baseline 6.96 (1.58 to 26.6) 6.42 (1.76 to 10.3) 0.48
After four cycles 1.85 (0 to 12.3) 1.87 (0 to 8.3) 0.96
After eight cycles 1.13 (0 to 8.7) 0.25 (0 to 5.6) 0.51
Positron emission tomography (PET) maximal standard uptake volume
(SUVmax) at baseline and after four cycles of chemotherapy (> 75% reduction
in SUVmax) according to histological cancer category. Data presented as
median (range) (total number = 60).
aMann-Whitney U test.
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and colleagues [25], evaluat e dg r o u p so fp a t i e n t sw i t h
mixed drug protocols. Given the various modes of
actions of these drugs on tumour cells, it is not surpris-
ing that statistically significant differences in metabolic
activity of the tumours may be observed on PET once
therapy is initiated. The mechanisms of drug responsive-
ness/resistance are not fully understood. Docetaxel and
FEC100 affect multiple pathways in tumour signalling
and growth. Docetaxel disrupts microtubules, enhances
apoptosis and affects angiogenesis [27,28], while FEC100
interferes with the synthesis of DNA and reduces mito-
tic and metabolic activity. Today, most combination
neoadjuvant chemotherapies involve docetaxel with
anthracyclines since this combination improves the
pathological response rates in primary breast cancers
and results in improved disease-free survival and overall
survival, at least in the adjuvant setting [28-30]. Never-
theless, randomised prospective studies are needed in
order to clarify how each drug protocol affects tumour
glucose metabolism and the appearance/activity on
serial FDG-PET studies.
SUV uptake values can be influenced by a range of
factors. Core or fine-needle aspiration biopsies can
potentially cause local inflammatory reaction, which
could affect SUV uptake and mask true tumour uptake.
This can impact on subsequent results and interpreta-
tion of the SUV values reported. In our study, the initial
(baseline) PET studies were carried out at least 10 to 14
days after the diagnostic core or fine-needle aspiration
took place, and are therefore unlikely to significantly
affect the SUV uptake recorded for the baseline imaging.
Once recruited, all women were biopsied only after the
PET imaging took place in order to avoid influencing
SUV measurements at the mid-treatment assessment.
The final PET imaging took place before surgical inter-
vention and hence did not have any impact on the third
PET imaging report.
Another potential influence on SUV measurements is
related to the variations of resting times that were per-
mitted during the study. The protocol in our centre sti-
pulates a 60 minute resting time prior to PET imaging.
This was adhered to in the great majority of patients.
On occasion, however, technical issues or delays in
workflow resulted in fluctuations of the resting time.
This was kept to a minimum whenever possible (varia-
tions of ± 15 minutes were permitted). Other factors
potentially resulting in SUV variation or inaccuracy
include partial volume effects (in which there is under-
estimation in small tumours), patient movement
between PET and CT, including respiratory motion, and
variation in FDG uptake time between initial and resta-
ging PET scans. Whilst variation in technique may
impact on the SUV measurements, it is very unlikely
that a marked reduction in SUV (75%) will occur purely
due to technical factors. Finally, we chose to report
SUVmax values rather than SUV mean values because
these are the values that are routinely reported to the
treating oncologists and also to facilitate comparison of
our results with those reported in the literature
[22-24,26].
Our study assessed tumour response after four cycles
of chemotherapy. Recent studies have shown that opti-
mal response evaluation exists as early as after two
cycles [22,23]. It would have been useful to have carried
out this earlier scan in our cohort of patients and to
compare the sensitivity and specificity with other pub-
lished studies. This should be investigated in future stu-
dies in order to obtain drug-specific response rates at a
stage during treatment when patients are not exposed to
several cycles of toxic and potentially ineffective therapy.
Our study was also limited by the heterogeneity of the
breast tumours in our cohort of women. This hetero-
geneity possibly contributed to the large variation of
SUVmax values observed at baseline among our patient
cohort and may be reflective of the variable biological
factors inherent to breast cancer.
We have previously observed a correlation between
PET SUV and a 12-gene signature [31]. Despite the
biological diversity of breast cancers in our cohort of
women, tumour type (ductal versus lobular) did not
appear to influence SUVmax uptake at any stage of
treatment (Table 6). There was no association
between residual nodal disease and PET response
according to histological types of cancer. Neverthe-
less, given the small number of women with lobular
or lobular/ductal breast cancer in our study (n = 10),
the next series of studies should investigate the rela-
tionship between various histological breast cancer
types, drugs and SUV uptake on FDG-PET in a larger
cohort of women. Such information will provide clini-
cians with better tools to direct individualised patient
management and predict treatment responses early on
during therapy.
Conclusions
Our results have shown that SUVmax uptake by breast
tumours on FDG-PET during neoadjuvant chemo-
therapy may be dependent on the drug regimen used.
T h ep r e d i c t i v ev a l u eo fF D G - P E Ta p p e a r st ob em o r e
useful in patients treated initially with anthracycline-
based chemotherapy rather than taxane-based
chemotherapy. Care must be taken when evaluating
FDG-PET in settings where patients receive varied drug
protocols. More studies are needed to clarify and stan-
dardise the relationships between tumour type,
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FDG-PET imaging.
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